Table of Contents
ISRN Gastroenterology
Volume 2013 (2013), Article ID 205417, 5 pages
Clinical Study

Experience with Oesophageal Cancer: A Ten-Year Single Centre Study Reflecting Daily Practice

Department of Internal Medicine and Gastroenterology, Zaans Medical Centre, P.O. BOX 210, 1500 EE Zaandam, The Netherlands

Received 28 February 2013; Accepted 27 March 2013

Academic Editors: A. K. Rishi and A. Weimann

Copyright © 2013 R. J. L. F. Loffeld and P. E. P. Dekkers. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Introduction. Studied patients with oesophageal cancer do not represent normal daily presentation. Aim. A retrospective study was done in all consecutive patients in order to describe presentation, treatment, and survival. Patients. All patients in a ten-year period were included. Patients were grouped in three groups. Group 1: no metastases and potentially curable, dead, or alive at time of evaluation. Group 2: patients presenting with metastases and treated with palliative chemotherapy, and group 3: patients with or without metastases but untreatable because of low Karnofsky index or important comorbidity rendering treatment not feasible. Results. One hundred thirty one evaluable patients were included. There was no difference in histological type of the tumour. Patients in group 3 were significantly older. Survival was not different between groups 2 and 3. Survival in group 1 was significantly longer ( ) compared with groups 2 and 3. Patients in group 1 received treatment with chemoradiation and surgery. Patients in groups 2 and 3 were more often treated with palliative chemotherapy and endoscopic stenting. Conclusion. The overall survival of oesophageal cancer in normal daily life is poor. Supportive care seems to be the best treatment option in patients with metastases or low Karnofsky index. Palliative chemotherapy does not add to overall survival.